View Older Stories View More Recent Stories

Jul 21, 2023 07:30AM Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Chil
Jun 16, 2023 04:30PM Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 4, 2023 07:00AM Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Apr 25, 2023 07:00AM Stoke Therapeutics Inc. (STOK) Receives Authorization to Initiate a Phase 1/2 Study of STK-002
Apr 25, 2023 07:00AM Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
Mar 15, 2023 07:02AM Stoke Therapeutics (STOK) Announces FDA Will Allow Administration of Higher Single Dose of STK-001 (70mg) in Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
Mar 15, 2023 07:00AM Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
Mar 6, 2023 07:00AM Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Feb 27, 2023 04:30PM Stoke Therapeutics to Participate at Upcoming March Investor Conferences
Feb 7, 2023 08:00AM Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
Jan 9, 2023 08:08AM Stoke Therapeutics (STOK) Highlights Strategic Priorities and Anticipated Milestones for 2023
Jan 9, 2023 08:00AM Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
Jan 4, 2023 08:00AM Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 2, 2022 09:00AM Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Soc
Nov 29, 2022 07:30AM Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting
Nov 14, 2022 07:00AM Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Nov 10, 2022 07:30AM Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome
Aug 25, 2022 07:30AM Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)
Aug 8, 2022 07:00AM Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Jun 1, 2022 07:30AM Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference
May 10, 2022 07:00AM Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 2, 2022 04:35PM Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002
Apr 7, 2022 07:30AM Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
Apr 5, 2022 07:30AM Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Mar 10, 2022 07:00AM Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
Feb 28, 2022 07:30AM Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference
Jan 10, 2022 07:06AM Acadia Pharma (ACAD), Stoke Therapeutics (STOK) Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
Jan 10, 2022 07:00AM Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
Jan 4, 2022 07:30AM Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 3, 2021 10:00AM Stoke Therapeutics Inc. (STOK) Reports Data from the Phase 1/2a MONARCH Study of STK-001
Dec 3, 2021 10:00AM Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting
Nov 19, 2021 11:54AM Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting
Nov 8, 2021 07:00AM Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Nov 3, 2021 07:30AM Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Sep 22, 2021 04:30PM Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual Conference
Sep 21, 2021 06:59AM Stoke Therapeutics (STOK) Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome
Sep 21, 2021 06:59AM Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome
Aug 10, 2021 07:00AM Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Aug 3, 2021 08:00AM Stoke Therapeutics to Present at Upcoming Investor Conferences in August
May 18, 2021 07:30AM Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference
May 10, 2021 07:30AM Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 4, 2021 08:00AM Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Au
Mar 30, 2021 07:31AM Stoke Therapeutics Inc. (STOK) Reports MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in U.K.
Mar 30, 2021 07:30AM Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom
Mar 24, 2021 07:30AM Stoke Therapeutics to Present at Upcoming Investor Conferences
Mar 9, 2021 07:30AM Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates
Mar 4, 2021 07:30AM Stoke Therapeutics to Present at the Barclays Global Healthcare Conference
Jan 4, 2021 04:05PM Stoke Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 4, 2020 04:05PM Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference
Dec 4, 2020 09:57AM Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilep
View More Recent Stories View Older Stories